1. Home
  2. LPSN vs ACET Comparison

LPSN vs ACET Comparison

Compare LPSN & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LivePerson Inc.

LPSN

LivePerson Inc.

HOLD

Current Price

$4.09

Market Cap

84.5M

Sector

Technology

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$7.85

Market Cap

71.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LPSN
ACET
Founded
1995
1947
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
84.5M
71.3M
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
LPSN
ACET
Price
$4.09
$7.85
Analyst Decision
Hold
Buy
Analyst Count
1
4
Target Price
N/A
$8.50
AVG Volume (30 Days)
202.7K
187.7K
Earning Date
11-10-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$257,660,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.91
$0.49
52 Week High
$31.20
$17.76

Technical Indicators

Market Signals
Indicator
LPSN
ACET
Relative Strength Index (RSI) 38.24 97.98
Support Level $3.91 $0.47
Resistance Level $4.18 $0.52
Average True Range (ATR) 0.26 0.09
MACD -0.08 0.48
Stochastic Oscillator 11.08 94.02

Price Performance

Historical Comparison
LPSN
ACET

About LPSN LivePerson Inc.

LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: